• 1
    Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res 2002; 52 (1–2): 177186.
  • 2
    Mesholam-Gately R, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23: 315336.
  • 3
    Niendam T, Jalbrzikowski M, Bearden C. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychol Rev 2009; 19: 280293.
  • 4
    Rinaldi M, Killackey E, Smith J, Shepherd G, Singh SP, Craig T. First episode psychosis and employment: a review. Int Rev Psychiatry 2010; 22: 148162.
  • 5
    Cahn W, van Haren NE, Hulshoff Pol HE et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry 2006; 189: 381382.
  • 6
    Subotnik K, Nuechterlein K, Ventura J et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168: 286292.
  • 7
    Penn D, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005; 162: 22202232.
  • 8
    Robinson DG, Woerner MG, McMenimen M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 473479.
  • 9
    Allott K, Liu P, Proffitt T, Killackey E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res 2011; 125 (2–3): 221235.
  • 10
    Milev P, Ho B, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia. a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 163: 495506.
  • 11
    Harvey PD, Helldin L, Bowie CR et al. Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. Am J Psychiatry 2009; 166: 821827.
  • 12
    Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163: 418425.
  • 13
    Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 2005; 28: 613633, 626.
  • 14
    Green M, Nuechterlein K. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 2004; 72: 13.
  • 15
    Bowie CR, Leung WW, Reichenberg A et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 2008; 63: 505511.
  • 16
    Keefe RS, Sweeney JA, Gu H et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 10611071.
  • 17
    Hawkins KA, Keefe RS, Christensen BK et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophr Res 2008; 105 (1–3): 19.
  • 18
    Jahshan C, Heaton RK, Golshan S, Cadenhead KS. Episode of schizophrenia. Neuropsychology 2010; 24: 109120.
  • 19
    Bilder RM, Goldman RS, Robinson D et al. Neuropsychological of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157: 549559.
  • 20
    Stirling JD, White C, Shon L et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res 2003; 65 (2–3): 7586.
  • 21
    Bartholomeusz CF, Allott K. Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence. Schizophr Res Treatment 2012; 2012: 115.
  • 22
    Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472485.
  • 23
    Hogarty GE, Flesher S, Ulrich R et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004; 61: 866876.
  • 24
    Spaulding WD, Reed D, Sullivan M, Richardson C, Weiler M. Effects of cognitive treatment in psychiatric rehabilitation. Schizophr Bull 2011; 37: 129137.
  • 25
    McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164: 17911802.
  • 26
    Vauth R, Corrigan PW, Clauss M et al. Cognitive strategies versus self-management skills as adjunct to vocational rehabilitation. Schizophr Bull 2005; 31: 5566.
  • 27
    Wexler BE, Bell MD. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr Bull 2005; 31: 931941.
  • 28
    Penades R, Boget T, Catalan R, Bernardo M, Gasto C, Salamero M. Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia. Schizophr Res 2003; 63: 219227.
  • 29
    Wykes T, Newton E, Landau S, Rice C, Thompson N, Frangou S. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res 2007; 94 (1–3): 221230.
  • 30
    Eack SM, Greenwald DP, Hogarty SS et al. Cognitive enhancement therapy for early-course schizophrenia: effects of two-year randomized controlled trial. Psychiatr Serv 2009; 60: 14681476.
  • 31
    Eack SM, Hogarty GE, Greenwald DP, Hogarty SS, Keshavan MS. Effects of cognitive enhancement therapy on employment outcomes in early schizophrenia: results from a 2-year randomized trial. Res Soc Work Pract 2010; 21: 3242.
  • 32
    Eack SM, Pogue-Geile MF, Greenwald DP, Hogarty SS, Keshavan MS. Mechanisms of functional improvement in a 2-year trial of cognitive enhancement therapy for early schizophrenia. Psychol Med 2010; 41 (6): 12531261.
  • 33
    Eack SM, Hogarty GE, Cho RY et al. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia. Arch Gen Psychiatry 2010; 67: 674682.
  • 34
    Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behaviour. Am J Psychiatry 2012; 169: 710718.
  • 35
    Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004; 68 (2–3): 283297.
  • 36
    Keefe RS, Harvey PD, Goldberg TE et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res 2008; 102 (1–3): 108115.
  • 37
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261276.
  • 38
    Patterson TL, Moscona S, McKibbin CL, Davidson K, Jeste DV. Social skills performance assessment among older patients with schizophrenia. Schizophr Res 2001; 48 (2–3): 351360.
  • 39
    Mausbach BT, Bowie CR, Harvey PD et al. Usefulness of the UCSD Performance-based Skills Assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res 2008; 42: 320327.
  • 40
    Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001; 27: 235245.
  • 41
    Heaton RK, Marcotte TD, Mindt MR et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10: 317331.
  • 42
    Patterson TL, Lacro J, McKibbin CL, Moscona S, Hughs T, Veste DV. Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol 2002; 22: 1119.
  • 43
    Schneider LC, Struening EL. SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr 1983; 19: 921.
  • 44
    McGurk SR, Mueser KT, Pascaris A. Cognitive training and supported employment with severe mental illness: one-year results from a randomized controlled trial. Schizophr Bull 2005; 31: 898909.
  • 45
    Cogpack. Version 5.1. Ladenburg, Germany: Marker Software, 2007.
  • 46
    Bracy OL. PSSCogRehab. Indianapolis, IN: Psychological Software Services Inc; 1994.
  • 47
    Scientific Brain Training PRO. [Cited 8 August 2012.] Available from URL:
  • 48
    Medalia A, Choi J. Cognitive remediation in schizophrenia. Neuropsychol Rev 2009; 19: 353364.
  • 49
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.
  • 50
    Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975983.
  • 51
    Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 17851804.
  • 52
    Rauchensteiner S, Kawohl W, Ozgurdal S et al. Test-performance after cognitive training in persons at risk mental state of schizophrenia and patients with schizophrenia. Psychiatry Res 2011; 185: 334339.
  • 53
    Urben S, Pihet S, Jaugey L, Halfon O, Holzer L. Computer-assisted cognitive remediation in adolescents with psychosis or at risk for psychosis: a 6-month follow-up. Acta Neuropsychiatr 2012; 6: 328335. doi: 10.1111/j.1601-5215.2012.00651.x.